Table 3 Tumor Rapamycin Levels
From: Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
| Â | 24 hours | 48 hours | ||||
|---|---|---|---|---|---|---|
Treatment Groups | Rapamycin Level (ng/ml) | p value* | Number of Mice | Rapamycin Level (ng/ml) | p value** | Number of Mice |
Treatment Trial (Tumor bearing) | Â | Â | Â | Â | Â | Â |
   0.4% Direct Topical Rapamycin | 13.8 ± 0.7 | 0.12 | 3 | 14.2 ± 1.8 | 0.33 | 3 |
   0.8% Indirect Topical Rapamycin | 34.2 ± 9.6 | 0.37 | 3 | 25.8 ± 7.8 | 0.65 | 3 |
   0.8% Direct Topical Rapamycin | 59.6 ± 23.5 | N/A | 3 | 21.0 ± 5.9 | N/A | 3 |
   0.16 mg Rapamycin IP | 421.8 ± 119.4 | 0.03 | 2 | 323.7 ± 98.1 | 0.03 | 2 |